Skip to main content

Table 1 Characteristics of the patients with Takayasu arteritis (n = 42)

From: Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis

Variables Value
Qualitative variables, number (percent)  
Sex, female:male 39:3
Class of vascular involvement  
1 4 (10%)
2A 4 (10%)
2B 3 (7%)
3 1 (2%)
4 0
5 30 (71%)
Coronary involvement 6 (14%)
Pulmonary artery involvement 13 (31%)
Aneurysms 16 (38%)
Steroids 30 (71%)
Immunosuppressive therapy 30 (71%)
Azathioprine 12 (29%)
Methotrexate 11 (26%)
Mycophenolate 4 (10%)
Sirolimus 2 (5%)
Cyclophosphamide 1 (2%)
Biologic therapy 19 (45%)
TNF-blockers 16 (38%)
Tocilizumab 2 (5%)
Rituximab 1 (2%)
Active disease (National Institutes of Health criteria) 12 (29%)
Vascular enhancement (n = 30) 5 (16%)
Vascular progression (n = 40) 9 (22%)
Scalar variables, mean, median (range)
Age, years 45, 46 (23 to 66)
Age at disease onset, years 33, 30 (17 to 56)
Disease duration, years 12, 10 (0 to 34)
Prednisone (PDN) dose, mg/day (n = 30) 9.2, 5 (3 to 35)
Erythrocyte sedimentation rate, mm/h 22, 15 (1 to 78)
Serum C-reactive protein, mg/l 6.2, 2.3 (0.1 to 40)
Serum Pentraxin-3, ng/ml 8.4, 5.5 (1.3 to 55)